Navigation Links
Insmed Provides Update on Follow-On Biologics and IPLEX(TM) Programs
Date:4/29/2008

an earlier stage of cell line development and product characterisation.

IPLEX(TM)

IPLEX(TM) is a complex of recombinant human insulin-like growth factor-I (rhIGF-I) and its predominant binding protein IGFBP-3 (rhIGFBP-3). The drug, approved in the United States in December 2005 for the treatment of children with growth failure due to severe primary IGF-I deficiency, is currently being investigated in Myotonic Muscular Dystrophy (MMD) and Amyotrophic Lateral Sclerosis (ALS), or Lou Gehrig's disease.

A Phase 2 trial of IPLEX(TM) in MMD is on-going and a substantial portion of the external costs associated with the study are expected to be covered by an approximately $2.1 million grant awarded to Insmed by the Muscular Dystrophy Association in late 2007.

MMD Phase 2 trial at-a-glance:

-- All sites have been initiated, received Investigational Review Board

approvals and are actively recruiting trial participants.

-- The trial is currently more than 50 percent enrolled.

-- The trial is on target to complete enrollment by mid-year 2008

-- Interim data analysis scheduled for fourth quarter 2008.

IPLEX(TM) is also in use as part of an Expanded Access Program (EAP) in partnership with the Italian Ministry of Health for the treatment of ALS. Since early 2007, the EAP has grown to include 20 physicians, and approximately 90 subjects have been enrolled into the program to date with additional subjects being enrolled as the program progresses. IPLEX(TM) continues to be safe and well tolerated in the subject population. During the first quarter of 2008, the EAP generated $2.3 million in cost recovery revenue for Insmed, compared to $0.7 million during the same period last year, and $2.0 million in the fourth quarter of 2007.

"We are pleased with the development progress and results to date of IPLEX(TM) in both MMD and ALS, especially considering the level of investment these therapeutic programs cur
'/>"/>

SOURCE Insmed Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Insmed Receives FDA Orphan Drug Designation for IPLEX(TM) in the Treatment of Myotonic Muscular Dystrophy
2. Insmed Provides Update on IPLEX(TM) Expanded Access Program in Italy for the Treatment of Amyotrophic Lateral Sclerosis
3. Insmed Launches National Awareness Campaign Surrounding Follow-On Biologics
4. Insmed Initiates Clinical Study for Follow-on Biologic Version of Neupogen(R)
5. CuraGen Provides Update on Velafermin, Belinostat and CR011-vcMMAE Clinical Development Programs
6. Access Pharmaceuticals Provides Update on Clinical Development Plan of ProLindac
7. Study Shows Combination Therapy Incorporating AVODART(R) and Tamsulosin Provides Continuous Symptom Improvement Over 2 Years
8. Raptor Pharmaceuticals Provides Update of Product Programs
9. Monogram Provides Update on Trofile(TM) Co-Receptor Tropism Assay
10. Arbios Provides Clinical Strategy for SEPET(TM) Pivotal Trial
11. Innocoll Provides a Progress Update on its Clinical Development Programs and Specialty Pharmaceutical Operations
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2015)... , Aug. 28, 2015 ... the addition of the "Investigation Report on China,s ... Tobramycin is a traditional antibiotic whose eye drop ... the treatment of potential infection or inflammation caused by ... China are able to produce tobramycin, among ...
(Date:8/28/2015)... , Aug. 28, 2015 ... announced the addition of the "Investigation Report ... their offering. Developed by Pharmacia & ... receptor agonist which effectively reduces intraocular pressure. As ... latanoprost (under the trade name of Xalatan) entered ...
(Date:8/28/2015)... , Aug. 28, 2015  Perrigo Company plc ... it has completed the acquisition of leading OTC brands ... €200 million. The transaction is a clear demonstration of ... Company,s leading European distribution network spanning 36 countries.  ... C. Papa commented, "We are excited to complete ...
Breaking Medicine Technology:Investigation Report on China's Tobramycin Market, 2015-2019 2China Latanoprost Market Investigation Report 2015-2019 2Perrigo Completes Acquisition of Leading Portfolio of OTC Brands from GSK 2Perrigo Completes Acquisition of Leading Portfolio of OTC Brands from GSK 3Perrigo Completes Acquisition of Leading Portfolio of OTC Brands from GSK 4
... management in the biopharmaceutical industry will "redouble efforts at ... intellectual property theft, counterfeiting and piracy, along with real ... a resolution unanimously adopted by the trustees ... the group applauds the ongoing efforts by labor and ...
... Inc. (NASDAQ: IDIX ), announced today that Idenix ... Life Sciences Conference on September 21, 2011 at 2:00 p.m. ... The live and archived webcast of the company ... Idenix Investor Center at www.idenix.com . Please log in ...
Cached Medicine Technology:PILMA Vows to 'Redouble' Support for Increased Protections Against Intellectual Property Theft 2
(Date:8/30/2015)... ... August 30, 2015 , ... ... medical devices for the treatment of prostate cancer, has announced the roll-out of ... at the treatment center in Puerto Vallarta, Mexico. , The Sonablate® technology currently ...
(Date:8/29/2015)... ... August 29, 2015 , ... On Saturday, September 19, 2015, Diane ... Foundation (Meso Foundation) will present an educational program titled “Asbestos and Your Health.” ... through 9:30 PM (doors open at 6:45pm) at Calvary United Methodist Church, 16 E ...
(Date:8/29/2015)... ... ... Dr. Tim Novelli, DC., Founder and President of the Patriot Project, is ... chiropractic field in the military. All too often VA hospitals treat patients with harmful ... to the VA program over a decade ago, the reality is that only 10% ...
(Date:8/29/2015)... ... 29, 2015 , ... People who have heart or lung ... asthma, are at higher risk from wildfire smoke especially in Calgary, Alberta.Those with ... problems (arrhythmia or irregular heartbeat) are also sensitive to air pollution. , ...
(Date:8/28/2015)... ... August 29, 2015 , ... Rio Salado College ... and the student experience as part of the EDUCAUSE - Next Generation Learning Challenges ... , This is the third Breakthrough Models Incubator hosted by EDUCAUSE and ...
Breaking Medicine News(10 mins):Health News:Image Fusion Technology Combines MRI and Ultrasound Images to Treat Prostate Cancer 2Health News:Mesothelioma Applied Research Foundation to Hold Educational Class About Asbestos and Mesothelioma Prevention 2Health News:The Patriot Project brings Chiropractic Care to the Armed Forces and their Families - Rapid Release Technology Joins the Effort to Recruit more Doctors to Pledge 2Health News:Heart Fit Clinic Sounds the Alarm on Forest Fire Smoke and Chronic Heart Disease in Calgary Area 2Health News:Rio Salado College Joins 9 Educational Leaders to Reinvent Higher Learning 2Health News:Rio Salado College Joins 9 Educational Leaders to Reinvent Higher Learning 3Health News:Rio Salado College Joins 9 Educational Leaders to Reinvent Higher Learning 4
... Test To Provide Physicians in U.S. and Europe ... , MADISON, N.J., June 2 HemoCue AB, an ... subsidiary of Quest Diagnostics Incorporated (NYSE: DGX ), ... Dynamics Corp (MEC) for the exclusive distribution of the Avie(TM) ...
... NEW YORK, June 2 , ... FOI Documents Through 1991 , ... clinical and post-marketing drug,information, has significantly expanded its coverage ... the launch of the FDA Classic,Collection. This collection contains ...
... June 2 Versus Technology, Inc. (Pink Sheets: VSTI) ... and OR Solutions to Chalmers P. Wylie Veterans Ambulatory ... rules-based real-time location information system (RTLiS) will be installed ... surgery center and clinics. , , The ...
... , , , Approval for ... Pa., June 2 B. Braun Medical Inc. (B. Braun), a ... U.S. Food and Drug Administration (FDA) approval for 2g ... DUPLEX(R) Drug Delivery System . , , (Logo: ...
... screens, researchers say , TUESDAY, June 2 (HealthDay News) -- ... more types of cancer than previously thought, a new study ... successfully used for early detection of colorectal cancer, researchers at ... also good at finding other gastrointestinal cancers, such as those ...
... that could influence the way researchers screen for, treat ... cancer, an aggressive form of the disease. One finding ... "Women with locally advanced breast cancer and their ... mass should not be ignored even if someone has ...
Cached Medicine News:Health News:Quest Diagnostics HemoCue AB Subsidiary to Add Avie(TM) Hemoglobin A1c to Diabetes Point-of-Care Test Suite 2Health News:Quest Diagnostics HemoCue AB Subsidiary to Add Avie(TM) Hemoglobin A1c to Diabetes Point-of-Care Test Suite 3Health News:Quest Diagnostics HemoCue AB Subsidiary to Add Avie(TM) Hemoglobin A1c to Diabetes Point-of-Care Test Suite 4Health News:Elsevier's PharmaPendium(TM) Introduces the FDA Classic Collection 2Health News:Elsevier's PharmaPendium(TM) Introduces the FDA Classic Collection 3Health News:Versus Technology, Inc. Announces Sale of Real-Time Location Information System to the Chalmers P. Wylie Veterans Clinic 2Health News:Versus Technology, Inc. Announces Sale of Real-Time Location Information System to the Chalmers P. Wylie Veterans Clinic 3Health News:B. Braun Anticipates Becoming First to Deliver FDA Approved 2g Cefazolin 2Health News:B. Braun Anticipates Becoming First to Deliver FDA Approved 2g Cefazolin 3Health News:Simple Test Could Detect More Gastrointestinal Cancers 2Health News:I-SPY trial offers key insights into locally advanced breast cancer 2Health News:I-SPY trial offers key insights into locally advanced breast cancer 3
... Gentian violet ink stands ... Millimeter scale ruler printed ... for quick measuring. Flexible, ... both inch and metric ...
Freer elevator, double end, 7 1/4", S/B....
Stainless steel dull finish....
The Ultima 2000 SE is flexible in meeting the needs of both office and operating room use. It is the answer for the clinical practice with a wide range of ophthalmic demands looking for minimal risk ...
Medicine Products: